Zydus Lifesciences532321Pharmaceuticals
Chandan Tapare recommended buying Zydus Lifesciences on dips
Heard on Live TV News Channel between 15:21:43 - 15:22:58 IST.
- Chandan Tapare said selective pharma counters are performing well and Zydus is holding steady despite broader market decline, indicating resilience and buying interest.
- He advised buying on any small dip with support at 1185, targeting 1250-1260 levels.
Also from Zydus Lifesciences
First-to-market generic of Adempas (Riociguat Tablets) launched in the U.S
5 Oct 2026
Closing date of 50:50 joint venture extended; completion now expected by December 2026
1 Oct 2026
Ruchit Jain of Motilal Oswal recommended buying Zydus Lifesciences citing pharma sector relative strength
29 Sep 2026
Source: Live TV News Channel · 28 Sep 2026
The call above is Chandan Tapare's, reported here as they made it. Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.